Vivo Opportunity, LLC's Form 4 filing
InMed Pharmaceuticals Inc. (INM) · filed Jul 2, 2026
- Accession no.
- 0001213900-26-075144
- Filed
- Jul 2, 2026, 7:02 PM ET
- Trade date
- Jun 30-Jul 2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions and 0 derivative transactions. Open-market purchases total $10.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Vivo Opportunity, LLCCIK 0001728970 | 10% Owner |
| Vivo Opportunity Cayman Fund, L.P.CIK 0001875722 | 10% Owner |
| Vivo Opportunity Cayman, LLCCIK 0001930113 | 10% Owner |
| Vivo Opportunity Fund Holdings, L.P.CIK 0001930214 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | Common Shares | PPurchaseAcquired | +545 | $1.54 | +$839.3 | 718,989 | Indirect | |
| Jun 30, 2026 | Common Shares | PPurchaseAcquired | +55 | $1.54 | +$84.7 | 72,590 | Indirect | |
| Jul 1, 2026 | Common Shares | PPurchaseAcquired | +3,946 | $1.55 | +$6,116.3 | 722,935 | Indirect | |
| Jul 1, 2026 | Common Shares | PPurchaseAcquired | +398 | $1.55 | +$616.9 | 72,988 | Indirect | |
| Jul 2, 2026 | Common Shares | PPurchaseAcquired | +1,460 | $1.55 | +$2,263 | 724,395 | Indirect | |
| Jul 2, 2026 | Common Shares | PPurchaseAcquired | +147 | $1.55 | +$227.85 | 73,135 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.